BioWorld

July 17, 2007

View Archived Issues

Affymax Clearing Pathway For Hematide In 'Murky' ESA Space

In the midst of increased regulatory scrutiny involving erythropoiesis-stimulating agents (ESAs), Affymax Inc. is forging ahead with a Phase III program of its anemia drug, Hematide, in chronic renal failure patients. (BioWorld Today) Read More

Novocell Gets $25 Million For Stem Cell Programs

Read More

Swiss Firm GlycoVaxyn Raises $9.5M For Vaccine Programs

Read More

Arpida's Iclaprim Wins Again In Phase III Study For cSSIs

Read More

Send In Your Stupid Biotech Ideas

Read More

Other News To Note

Read More

Clinic Roundup

Read More